Actively Recruiting
Global Phase 3 Study Evaluating Long-Term Safety and Tolerability of Oral NBI-1117568 in Adults with Schizophrenia
Led by Neurocrine Biosciences · Updated on 2026-09-25
600
Participants Needed
61
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the long-term safety of the drug NBI-1117568 in adults diagnosed with schizophrenia. This phase 3, open-label trial aims to understand how well participants tolerate this medication when taken daily over an extended period. The study is sponsored by Neurocrine Biosciences and focuses on monitoring treatment-emergent adverse events. Participants will receive NBI-1117568 orally once a day for up to 36 months. This single-group study does not include a placebo or comparator arm. The treatment duration allows researchers to assess safety and tolerability during continuous daily use over three years. During the study, participants will have regular assessments to monitor any adverse effects associated with the drug. Researchers will track the number of participants experiencing treatment-emergent adverse events throughout the 36-month period. The study includes adults aged 18 to 65 years who have a primary diagnosis of schizophrenia and reside in stable housing, and it excludes those with certain medical conditions or substance use disorders. Participants will be closely observed to ensure adherence to the study protocol and safety monitoring.
CONDITIONS
Brief Title
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Research Team
N
Neurocrine Medical Information Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here